tradmap

BON Bon Natural Life Ltd

$1.11 -2.19%

Data as of close

Healthcare · Medicinal Chemicals & Botanical Products

Bon Natural Life Ltd (BON) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $3 million. Shares last traded at $1.11, 46.7% below their 52-week high. Over the past year the stock is down 27.1%. Net profit margin is -10.7%, below the peer median of -8.8%. Revenue declined 21.7% year over year.

Market Cap
$3M
Shares Out
2.8M
EPS (TTM)
-$0.72
P/E (TTM)*
—
P/S Ratio
0.16
P/B Ratio
0.05
Dividend / Share
—
Dividend Yield
—
52-Week High
$2.09
52-Week Low
$1.07
Volume (venue)
425
Avg Vol (3m, venue)
246.889

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+0.00%
1M
+0.00%
3M
—
6M
—
YTD
-25.67%
1Y
-27.12%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. BON split history →

Technicals

RSI (14)
45.40
SMA (50)
$1.15
SMA (200)
$1.52
Price vs SMA50
-2.80%
Price vs SMA200
-26.83%
ATR (14)
$0.03

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$19M
Net Income
-$2M
Gross Margin
20.8%
Operating Margin
-8.7%
Net Margin
-10.7%
Return on Equity
-3.5%
Return on Assets
-2.3%
Current Ratio
1.74
Debt / Equity
0.03
Revenue Growth (YoY)
-21.7%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2025-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Medicinal Chemicals & Botanical Products peers

BON vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close

P/S vs peers
0.16 / 0.58 med
-72% discount
Net margin vs peers
-10.7% / -8.8% med
below median
1–14 of 14
DFTXDefinium Therapeutics, Inc.$4.4B———-10.70%
RGCRegencell Bioscience Holdings Ltd$3.1B———-5.00%
TRLVTrulieve Cannabis Corp.$2.1B—1.88-41.8%+8.19%
CRONCronos Group$1.2B17.646.8939.1%+1.52%
TLRYTilray Brands$375M—0.39-17.1%+0.40%
SNDLSNDL Inc.$337M———+2.81%
CGCCanopy Growth$288M—1.37-80.0%+4.07%
USNAUSANA HEALTH SCIENCES INC$271M—0.30-2.4%+2.69%
ACBAurora Cannabis$237M———+3.94%
GLASGlass House Brands Inc.$192M—1.05-16.3%+6.85%
NAGENiagen Bioscience, Inc.$190M11.881.4712.4%+2.56%
MDWDMediWound Ltd.$173M———+1.35%
FTLFFITLIFE BRANDS, INC.$78M12.450.776.2%+4.69%
BTMDbiote Corp.$33M5.560.183.2%+1.79%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.